Draft:Positive Bioscience

Caris Life Sciences Showcases Data on KRAS Mutations in Patients With Non-Small Cell Lung and Pancreatic Cancer at ASCO20 Virtual Scientific Program

Retrieved on: 
Friday, May 29, 2020

The poster is titled, "Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC)."

Key Points: 
  • The poster is titled, "Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC)."
  • Caris will present additional data from studies highlighting the distinct molecular landscapes of patients across several cancer types, including mesothelioma and gastroesophageal cancers.
  • Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation.
  • Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets.

Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

Retrieved on: 
Tuesday, January 14, 2020

SALT LAKE CITY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Thomas P. Slavin, M.D., FACMG, DABMD, senior vice president of Medical Affairs at Myriad Oncology effective March 2, 2020.

Key Points: 
  • SALT LAKE CITY, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Thomas P. Slavin, M.D., FACMG, DABMD, senior vice president of Medical Affairs at Myriad Oncology effective March 2, 2020.
  • In this role, Dr. Slavin will provide medical and scientific leadership across Myriad's portfolio of molecular and companion diagnostic products and services for oncology.
  • Thomas leadership in hereditary cancer makes him a great fit for Myriad Oncology, said Ms. Lambert.
  • I am excited to join Myriad Oncology and lead the medical team as we work to advance precision medicine in oncology, said Dr. Slavin.

University of Minnesota Joins Precision Oncology Alliance Led by Caris Life Sciences

Retrieved on: 
Tuesday, November 26, 2019

IRVING, Texasand MINNEAPOLIS, Nov. 26,2019 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that the University of Minnesota has become the 31st member of its Precision Oncology Alliance .

Key Points: 
  • IRVING, Texasand MINNEAPOLIS, Nov. 26,2019 /PRNewswire/ --Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that the University of Minnesota has become the 31st member of its Precision Oncology Alliance .
  • Through the Precision Oncology Alliance powered by Caris the University of Minnesota Masonic Cancer Center will partner with other notable cancer centers and academic institutions to broaden patient access to precision cancer care, have early access to Caris' Next Generation Profiling offerings, and establish evidence-based standards for tumor profiling and molecular testing in oncology.
  • We look forward to collaborating with Caris Life Sciences and the members of the Precision Oncology Alliance to progress innovative research that will fuel the next great discoveries in precision medicine."
  • Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation.